HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David Royston Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Royston, D. Search for Related Content PubMed Articles by Royston, D. Related Collections Cardiac - pharmacology

J Thorac Cardiovasc Surg 2008;136:798-799
© 2008 The American Association for Thoracic Surgery

Letter to the Editor

Aprotinin; An economy of truth?

Consultant Anaesthetist, Royal Brompton and Harefield NHS Trust, Harefield, UK

The first 20% of the full text of this article appears below.

To the Editor:

I write to comment on the editorials by Drs Sundt¹ (April 2008) and Westaby² (March 2008). Dr Sundt is perceptive but fails to consider that the observational studies suggesting a danger with aprotinin may have had bias in the analysis.

At the advisory committee meeting of the Food and Drug Administration (FDA) held on September 12, 2007, Dr Mangano allowed the FDA access to the McSPI (Multicenter Study of Perioperative Ischemia) data set. Whereas Mangano and colleagues³ used a propensity score that was based on likelihood of bleeding, the FDA reanalysis of these data used stratification according to risk of . . . [Full Text of this Article]

This article has been cited by other articles:

				D. L. Ngaage and J. M. Bland Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies Eur J Cardiothorac Surg, June 1, 2010; 37(6): 1375 - 1383. [Abstract] [Full Text] [PDF]